Evidence map›Paper›PMID 41491064›Full record

ArticleScientific reports2026

Biological and prognostic relevance of A-to-I RNA editing across consensus molecular subtypes of colon cancer.

Dario Monaco, Debora Traversa, Eliseo Mattioli, Francesco Alfredo Zito, Grazia Cristiani, Francesca Buono, Sabina Delcuratolo, Tiziana Guarino, Rosamaria Pinto, Antonia Lasorella and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dario Monaco *Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Debora Traversa *Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Eliseo MattioliPathology Department, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Francesco Alfredo ZitoPathology Department, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Grazia CristianiPathology Department, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Francesca BuonoMolecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Sabina DelcuratoloClinical Trial Office, IRCCS-Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Tiziana GuarinoMedical Oncology, SG Moscati Hospital, Statte, 74010, Italy.
Rosamaria PintoMolecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Antonia LasorellaMolecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Rosanna LacalamitaMolecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Ernesto Picardi *Department of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, Bari, BA, Italy.
Stefania Tommasi *Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy.
Simona De Summa *Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Via O. Flacco n. 65, Bari, 70124, Italy. s.desumma@oncologico.bari.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the second most frequently diagnosed cancer worldwide and represents a major challenge for public health. Despite advances in molecular profiling, important gaps remain in our understanding of tumorigenesis and the regulatory mechanisms underlying CRC progression. The most widely adopted classification system is the Consensus Molecular Subtypes (CMS), which stratifies CRC into four biologically distinct subtypes. We investigated the role of A-to-I RNA editing across CMS subtypes in a cohort of 100 CRC patients at various disease stages. Bulk RNA-seq data were analyzed using REDItools to detect editing events, focusing on both recoding sites and edits within repetitive elements, such as Alu sequences. Furthermore, expression levels of the ADAR enzyme family were assessed, and deconvolution analyses were performed on single-cell RNA-seq data from an independent cohort of stage II CRC patients to characterize editing activity within the tumor microenvironment (TME). Competitive endogenous RNA (ceRNA) networks, specific to each CMS subtype, were constructed based on editing events in repetitive elements. A multivariate Cox proportional hazards model was applied to evaluate associations with overall survival (OS). We observed statistically significant differences in ADARB1 expression across CMS subtypes. Single-cell RNA-seq data revealed subtype-specific distribution patterns of ADAR enzymes within the TME. Analysis of editing events showed subtype-specific signatures in both known cancer-related genes (e.g., COPA, CADPS, IGFBP7) and novel candidates (ZNF552, RALGPS1). Editing in repetitive elements informed the construction of distinct ceRNA networks for each CMS subtype, suggesting different post-transcriptional regulatory mechanisms. Survival analysis identified three variables significantly associated with OS, independent of CMS classification and clinical stage: ADARB1 expression, and editing events in NOP14-AS1 (chr4:2960236; p = 0.036; HR = 0.0069), previously linked to 5-FU sensitivity, and ST7-AS2 (chr4:117120557). This study underscores the biological relevance of RNA editing in CRC, highlighting its impact on chemoresistance, the tumor microenvironment, and subtype-specific gene regulation. Our findings suggest that RNA editing represents a critical post-transcriptional regulatory layer in CRC and holds potential as a biomarker and therapeutic target.

Indexed as

Colonic NeoplasmsRNA EditingAdenosine DeaminaseAgedBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisRNA-Binding ProteinsTumor MicroenvironmentADARB1 protein, humanAdenosine DeaminaseBiomarkers, TumorRNA-Binding ProteinsADAR enzymesCeRNA network tumor microenvironment (TME)ChemoresistanceConsensus molecular subtypes (CMS)Post-transcriptional regulationRNA editingSurvival analysis

Identifiers

PMID41491064
PMCPMC12855204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.